Financial Report: Alkermes 2Q

Alkermes

2Q Revenues: $124.0 million (+72%)

2Q Loss: $16.7 million (loss of $22.3 million 2Q12)  

YTD Revenues: $276.2 million (+106%)

YTD Earnings: $5.7 million (loss of $35.5 million YTD12)

Comments: Manufacturing and royalty revenues for Risperdal Consta and Invega Sustenna/Xeplion were $50.3 million in the quarter, up 12%, with worldwide end-market sales of $564 million, up 15%. Manufacturing and royalty revenues from Ampyra/Fampyra were $5.0 million, compared to $0.6 million in fiscal 2Q12 and end-market sales by Acorda Therapeutics, in the U.S. were $69.8 million, up 28%. Vivitrolsales were $15.2 million, compared to $9.9 million in fiscal 2Q12. Royalty revenue from Bydureon was $3.3 million, compared to $0.1 million for fiscal 2Q12. Earnings include a one-time charge of $12.1 million related to refinancing the company’s debt in September 2012.